Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.

Venus Medtech (Hangzhou) Inc.

杭州启明医疗器械股份有限公司 is engaged in the research, development, and industrialization of transcatheter treatment products for structural heart diseases. The company offers a range of structural heart disease solutions, including products for aortic valve, pulmonary valve, mitral, tricuspid valve diseases, and hypertension treatment.

COM:VENUSMEDTECH

杭州启明医疗器械股份有限公司

Last Close

5.62

23/07 20:00

Market Cap

2.46B

Beta: -

Volume Today

6.42M

Avg: -

Financials Not Available